Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15194564 | 0.97 | ALDH1A1 (0.36) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL15194472 | 0.97 | ALDH1A1 (0.36) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL9726985 | 0.97 | ALDH1A1 (0.36) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL9853462 | 0.92 | ALDH1A1 (0.36) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL3237003 | 0.92 | ALDH1A1 (0.36) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL1350511 | 0.92 | ALDH1A1 (0.36) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL9853465 | 0.90 | ALDH1A1 (0.35) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL1742367 | 0.90 | ALDH1A1 (0.39) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL8510561 | 0.90 | ALDH1A1 (0.39) | ALDH1A1CTSLCTSBCTSSCTSK | |
| SCHEMBL1347911 | 0.90 | ALDH1A1 (0.35) | ALDH1A1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2814822-B1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| WO-2013120921-A9 | NOVEL PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-10-08 | — | — | WO | disclosed |
| EP-2814822-A1 | NOVEL PYRROLIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-8802665-B2 | Pyrrolidine derivatives | GENENTECH, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| WO-2013120921-A1 | NOVEL PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-08-22 | — | — | WO | disclosed |
| US-20130217665-A1 | NOVEL PYRROLIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063098-B2 | GlyT1 receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010020548-A1 | GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020548-A1 | GLYT1 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2010-02-25 | — | — | US | disclosed |
| EP-1170281-B1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2005-12-21 | — | — | EP | disclosed |
| US-6943184-B2 | 1,1- and 1,2-disubstituted cyclopropane compounds | LES LABORATORIES SERVIER (FR) | 2005-09-13 | — | — | US | disclosed |
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | GOLDSTEIN SOLO (FR) | 2005-02-10 | — | — | US | disclosed |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | ADIR ET COMPAGNIE (FR) | 2002-02-21 | — | — | US | disclosed |
| EP-1170281-A1 | 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032845-A1 | 1,1-and 1,2-disubstituted cyclopropane compounds | CHRNA1, CHRNA4, CHRNB1 | ALDH1A1 582/4885CTSL 3363/4885CTSB 3767/4885 |
| US-20020022643-A1 | 1,1- and 1,2-disubstituted cyclopropane compounds | HCAR1, CHRNA1, CNR1 | ALDH1A1 575/4885CTSL 2427/4885CTSB 3216/4885 |
| US-20100048531-A1 | GlyT1 RECEPTOR ANTAGONISTS | GLRA1, GLRA2, GRIA1 | ALDH1A1 1116/4885CTSL 4550/4885CTSB 4234/4885 |
| US-20130217665-A1 | NOVEL PYRROLIDINE DERIVATIVES | PYCR1, ADCYAP1R1, AVPR1A | ALDH1A1 121/4885CTSL 1396/4885CTSB 1721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.